Clinical trials: Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation
This open label phase-II trial evaluates hematological response of an additional treatment with 5-Azacitidine to common DLI in patients with MDS or AML relapsing after allogeneic stem cell transplantation.
- Trial name
- NCT00795548
- Testing
- 5-Azacitidine
- Where
- 6 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
The protocol treatment is to evaluate clinical effects of donor-derived natural killer cells that are given after HLA-mismatched hematopoietic cell transplantation.
- Trial name
- DNKI-II (NCT01795378)
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Asan Medical Center
Leukemia, Lymphoma
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
The purpose of this study is: 1. To establish the maximally tolerated dose (MTD) of intravenous busulfan (Busulfan®) in combination with fludarabine as conditioning regimen for transplantation with in-vivo T-cell depletion. 2.
- Conditions
- Leukemia, Lymphoma, Myeloma
- Trial name
- NCT00943319
- Testing
- Busulfan, Fludarabine, Campath
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
GVHD, AML
Haplo Peripheral Blood Sct In GVHD Prevention
This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative…
- Conditions
- GVHD, AML, ALL, MDS
- Trial name
- NCT04473911
- Testing
- FLUDARABINE, CYCLOPHOSPHAMIDE, TBI
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Zachariah Michael DeFilipp
ADA-SCID
Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene
The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID infants and children following human ADA cDNA…
- Trial name
- NCT01852071
- Testing
- Infusion of autologous EFS-ADA LV CD34+ (OTL-101), busulfan, PEG-ADA ERT
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of California, Los Angeles
Leukemia, Lymphoma
Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells.
- Trial name
- NCT00002700
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 44 sites in Belgium, Croatia and 8 more
- Volunteers
- 392 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-Hodgkin's Lymphoma
Allo-hNHL (FluBuCy)
DSHNHL R3 is a randomized clinical phase II study. The main objective is to estimate the efficacy of rituximab as a prophylactic medication for prevention of graft-versus-host-disease after allogeneic peripheral stem cell…
- Trial name
- NCT00785330
- Testing
- standard GVHD prophylaxis, rituximab
- Where
- 6 sites in Germany
- Volunteers
- 84 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Osteochondritis of the Femoral Head
Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head
Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties. Bone marrow mononuclear cells (BMMNCs) have revascularization properties and complimentary effects to MSCs.
- Trial name
- NCT00813267
- Testing
- mesenchymal stem cell infusion, bone marrow mononuclear cell infusion
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Jianming Tan
Diffuse Large B-cell Lymphoma
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma
The purpose of the Phase I of the study is to evaluate the safety and the maximum-tolerated dose (MTD) of the combination R-ESHAP with lenalidomide as salvage therapy for patients with relapsed or refractory diffuse large B-cell…
- Trial name
- NCT02340936
- Testing
- LR-ESHAP (lenalidomide 5 mg), LR-ESHAP (lenalidomide 10 mg), LR-ESHAP (lenalidomide 15 mg)
- Where
- 9 sites in Spain
- Volunteers
- 53 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
BK Virus Infection
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
This research study is evaluating the reactivation of BK virus in patients who have undergone allogeneic hematopoietic-cell transplantation.
- Trial name
- NCT03532971
- Testing
- Symptom index questionnaire, BK polyomavirus PCR, quality of life questionnaires
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Beta-Thalassemia
A Long-term Follow-up Study in Participants Who Received CS-101
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.
- Trial name
- NCT06685536
- Testing
- Safety and efficacy assessments
- Where
- China
- Volunteers
- 5 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
This randomized allogeneic transplantation protocol compares i.v. Treosulfan-based conditioning therapy with reduced intensity i.v.
- Trial name
- NCT00822393
- Testing
- Busulfan, Treosulfan
- Where
- 33 sites in Finland, France and 4 more
- Volunteers
- 570 people
- Sponsor
- medac GmbH
GVHD,Acute, Biomarker
Role of aGVHD Biomarkers on aGVHD Risks
To establish risk rating criteria of biological protein marker, determine the role and consistency of aGVHD biomarkers in aGVHD diagnosis and aGVHD prognosis, and evaluate the the impact on non-relapse mortality and relapse and…
- Trial name
- GVHD (NCT04284904)
- Testing
- aGVHD biomarker
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Chinese PLA General Hospital
Mantle Cell Lymphoma
Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
1. Rationale In mantle cell lymphoma, the conventional chemotherapy achieves only temporary responses with a median duration of remissions only from 1 to 2 years.
- Trial name
- ZOLINZA (NCT01578343)
- Testing
- Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Peripheral T Cell Lymphoma
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR
This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the observation group and the autologous hematopoietic stem cell transplantation group (Auto-HSCT).
- Trial name
- T-START-CR (NCT07353840)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Observation
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hematologic Malignancies
Phase II Trial of Pentostatin and Targeted Busulfan
The objective of this trial is to determine whether a regimen of pentostatin and busulfan (IV) can facilitate engraftment of human leukocyte antigen (HLA) partially compatible siblings and unrelated donor transplants by using…
- Trial name
- Pento & tBU (NCT00496340)
- Testing
- Pentostatin, Busulfan, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Graft Versus Host Disease, Leukemia
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00002790
- Testing
- cyclosporine, methotrexate, sirolimus
- Sponsor
- Fred Hutchinson Cancer Center
Graft Versus Host Disease, Hematopoietic Cell Transplantation Recipient
Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
This pilot clinical trial studies how well a gluten free diet works in preventing graft versus host disease in patients who are undergoing a donor stem cell transplant.
- Trial name
- NCT03102060
- Testing
- Dietary Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rutgers, The State University of New Jersey
CD19-chimeric Antigen Receptor T Cells, Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
Building a new haploid transplanted model with high-dose CTX、CD19-CART,donor CD34+ hematopoietic stem cell and Tregs,to prevent graft-versus-host disease(GVHD),reduce the infection,promote the rate of immune…
- Conditions
- CD19-chimeric Antigen Receptor T Cells, Relapsed and/or Refractory Acute Lymphoblastic Leukemia, the Haploidentical Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03423706
- Testing
- the new model of haplo-HSCT for r/r B-ALL
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Hematopoietic Stem Cell Transplant
Time Restricted Nutrition in Pediatric Stem Cell Transplant Recipients
Circadian cycles, metabolism, and nutrition are intimately linked, and the timing of meals play an important role in synchronizing peripheral circadian rhythms.
- Trial name
- NCT04549038
- Testing
- 12-16 hour nutrition
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.